SII applies for full market authorisation of Covishield as supplies of vaccine exceeded 125 crore doses

SII had partnered with the developer of Covishield, AstraZeneca, for the supply of the vaccine to the Indian government
Image for representational purpose only. (Photo | AP)
Image for representational purpose only. (Photo | AP)

NEW DELHI: Serum Institute of India (SII) CEO Adar Poonawala on Friday said it has applied to Indian authorities for full market authorisation of Covishield, stating supplies of the COVID-19 vaccine have exceeded 125 crore doses.

SII had partnered with the developer of Covishield, AstraZeneca, for the supply of the vaccine to the Indian government, which had in January this year granted emergency use authorisation in the country.

"Supplies of the COVISHIELD vaccine in India, have exceeded 1.25 billion doses. The government of India now has enough data for full market authorisation, and therefore @SerumInstIndia has applied to the @CDSCO_INDIA_INF (DCGI) and @MoHFW_INDIA for this permission," Poonawala said in a tweet tagging the Central Drugs Standard Control Organisation (CDSCO) and Ministry of Health and Family Welfare.

Related Stories

No stories found.
The New Indian Express
www.newindianexpress.com